A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma

Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS

(2013) Takashi Yoshioka et al.   GYNECOLOGIC ONCOLOGY

Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules

(2012) H. Taniguchi et al.   MOLECULAR CANCER THERAPEUTICS

ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma

(2012) Jennifer S. Carew et al.   PLoS One

Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

(2011) B. Ramaswamy et al.   BREAST CANCER RESEARCH AND TREATMENT

JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma

(2011) T Kanno et al.   ONCOGENE

Targeting mTOR in renal cell carcinoma

(2010) Gary R. Hudes   CANCER

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Histone Deacetylase Inhibitors and 15-Deoxy- 12,14-Prostaglandin J2 Synergistically Induce Apoptosis

(2010) M. Koyama et al.   CLINICAL CANCER RESEARCH

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

(2010) M. B. Wozniak et al.   HAEMATOLOGICA

Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling

(2010) Ying Qu et al.   JOURNAL OF CLINICAL INVESTIGATION

Blockade of the ERK or PI3K–Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib

(2009) Kei-ichi Ozaki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

(2009) D. Mahalingam et al.   CLINICAL CANCER RESEARCH

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

(2008) Florian R Fritzsche et al.   BMC CANCER

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

(2008) Kiran Gupta et al.   CANCER TREATMENT REVIEWS

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

(2008) A. C. Mita et al.   CLINICAL CANCER RESEARCH